Funding for TripleMed to obtain CE marking
Solutions for better treatment of aortic aneurysms one step closer
TripleMed BV is a medical start-up focused on improving the treatment of aortic aneurysms. A consortium of existing and new investors has contributed more than two million euros to enable the clinical studies required for CE marking and market introduction. The aim is to achieve CE marking in early 2025. LIOF previously invested through the Limburg Business Development Fund (LBDF) and has now acquired a stake in the company through the Participation Fund. Existing shareholder Brightlands Venture Partners has reinvested in TripleMed through its Chemelot Ventures fund.
Lenn Houbiers, investment manager at LIOF: "In the long term, the TripleMed solution will ensure a more efficient approach to aortic aneurysms, a better quality of life and lower healthcare costs. TripleMed is thus making an important contribution to the health transition, one of the transitions that LIOF is strongly committed to."
Solutions under development
TripleMed is currently conducting clinical trials at a number of hospitals in the Netherlands and Belgium to validate AneuFix Endoleak Repair (repairing a leak after an aneurysm operation) and AneuFill Prophylactic Sac Filling (preventive insertion of a polymer to prevent leaks). The AneuFix/AneuFill concept is a two-component polymer in a syringe. Upon insertion, the two components are mixed and then harden into a permanently elastic implant in the aneurysm.
Clinical trials commenced in 2020, and to date, 33 patients have been treated. The interim results of the clinical trial are very positive, with 89% of patients experiencing long-term leakage control. By the end of 2024, the company hopes to have treated 57 patients and thus completed the clinical trial so that the CE mark for AneuFix can be obtained, followed in 2026 by the CE mark for Aneufill.
“We are delighted with the new financial injection, which will enable us to continue our research and obtain the certification required for the market launch of both products.”
Tjeerd Homsma, Chief Executive Officer of TripleMed
Size of aortic aneurysms
Every year, more than 150,000 patients worldwide are treated for aortic aneurysms. No less than 10-15% of all aortic aneurysms previously treated with stent grafts experience leaks and further growth of the aneurysm. There is currently no effective treatment for this.
___________________________________________________________________
Over TripleMed
TripleMed was founded in 2011 by three vascular surgeons, Dr Hans Brom, Dr Alexander de Vries and Prof. Dr Michael Jacobs. The company is based at the Brightlands Chemelot Campus in Geleen. TripleMed focuses on developing innovative and cost-effective solutions for the treatment of aortic aneurysms.
Despite the obvious advantages of endovascular treatments using endoprostheses, the procedure is associated with a relatively high number of complications and repeat procedures in the years following the initial procedure, which has a major impact on patients' quality of life and entails high costs. With its products, TripleMed expects to deliver a significant improvement in the more effective and cost-efficient treatment of aortic aneurysms. More information is available at www.triplemedical.com.
About Brightlands Venture Partners
Brightlands Venture Partners is the fund manager of Chemelot Ventures and is a so-called ecosystem investor. It invests in innovative companies that can benefit from and contribute to the ecosystem of the Brightlands campuses in the south of the Netherlands. Other funds under management include BVP Fund IV, Brightlands Agrifood Fund and Limburg Ventures. Chemelot Ventures has a portfolio of investments in start-ups and scale-ups in the field of sustainability and health. To date, the funds have made a total of more than 50 investments.
Further information is available at https://brightlandsventurepartners.com/.
Want to know more?
Want more information or to know how LIOF can help your company move forward? Feel free to contact us!